Randomized Embolization Trial for NeuroEndocrine Tumour Metastases To The Liver

Official Title

Randomized Embolization Trial for NeuroEndocrine Tumour Metastases To The Liver

Summary:

The primary aim of this trial is to estimate the duration of hepatic progression-free survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary hypothesis is that chemoembolization will be nearly twice as durable as bland embolization; thatis, the hazard ratio for HPFS will be 1.76 or better.

Trial Description

Primary Outcome:

  • Abdominal MRI/Triple Phase CT
Secondary Outcome:
  • Number of Adverse Events

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society